Novartis
To discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering.
Launch date
Employees
Market cap
€212.5b
Enterprise valuation
€231.2b (Public information from Sep 2024)
Share price
$115.97 NVS
Company register number CHE-106.054.058
Basel Canton of Basel-Stadt (HQ)
Corporate Venture Fund: dRx Capital, Novartis Venture Fund
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 49.9b | 52.9b | 51.8b | 46.7b | 49.7b | 52.0b | 52.5b |
% growth | 3 % | 6 % | (2 %) | (10 %) | 7 % | 5 % | 1 % |
EBITDA | 17.2b | 33.1b | 16.4b | 18.5b | 19.6b | 21.1b | 21.7b |
% EBITDA margin | 34 % | 63 % | 32 % | 40 % | 39 % | 41 % | 41 % |
Profit | 8.1b | 24.0b | 7.0b | 14.9b | 11.0b | 12.4b | 13.4b |
% profit margin | 16 % | 45 % | 13 % | 32 % | 22 % | 24 % | 25 % |
EV / revenue | 4.8x | 3.9x | 3.9x | 4.7x | 5.1x | 4.9x | 4.8x |
EV / EBITDA | 13.9x | 6.2x | 12.4x | 11.9x | 13.0x | 12.0x | 11.6x |
R&D budget | 9.0b | 9.5b | 10.0b | 11.4b | - | - | - |
R&D % of revenue | 18 % | 18 % | 19 % | 24 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
$6.5m | Grant | ||
Total Funding | €5.9m |
Recent News about Novartis
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
By Country
By Industry
ACQUISITION by Novartis Dec 2016
ACQUISITION by Novartis Dec 2016
exited
ACQUISITION by Novartis Dec 2009
exited
exited
exited
ACQUISITION by Novartis Nov 2019
ACQUISITION by Novartis Nov 2018